If this is your first time accessing any of the Presentations from JADPRO Live at APSHO 2016, please take a moment to create an account using the Register link to the right. Otherwise, please log in with your username and password to proceed. Please contact firstname.lastname@example.org with any questions.
A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.
This activity is supported by an educational grant from Merck & Co.
Release date: January 17, 2017 Estimated time to complete activity: 1.0 hours
Expiration date: January 17, 2018
Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Cancer Institute
Activity Rationale and Purpose
Immunotherapy is a rapidly growing therapeutic area of oncology. This new class of oncology agents brings a more favorable adverse effect profile than traditional chemotherapeutic agents, and in some cases, efficacy continuing beyond the treatment window. It was only in 2011 that the first immune checkpoint inhibitor was approved. Since 2011, three other immunotherapeutic agents for cancer were FDA approved, and numerous clinical trials with immunotherapeutic agents are underway for patients with other types of cancer including advanced lung, kidney, bladder, head and neck cancers, and Hodgkin lymphoma. Increased education is needed for the results of research to be translated into clinical practice. With these novel agents making their way quickly into treatment recommendations and guidelines, providers need to stay current to provide patients with a balance of both efficacy and safety.
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.
After completing this educational activity, participants should be able to:
- Manage the treatment plan for patients treated with immunotherapeutic agents, factoring in the concept of pseudoprogression
- Counsel patients on the necessity of PD-L1 biomarker testing in advance of initiating immunotherapy regimens
- Summarize the role of PD-L1 in patients set to receive immunotherapeutic regimens for melanoma
The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
A maximum of 1.0 contact hours may be earned for successful completion of this activity.
This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Anthony J. Olszanski, MD, RPh, has received research support from Advaxis, Bristol-Myers Squibb, EMD Serono, GSK, Ignytaa, Immunocore, Incyte, Kyowa, Lilly, Merck, Mirati, Novartis, Pfizer, and Takeda. He has and served as a consultant for Bristol-Myers Squibb, Churchill/iCeutica, Janssen, Merck, and Takeda
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, served on an advisory board for Astra Zeneca.
Lead Nurse Planner
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.
Annenberg Center for Health Sciences at Eisenhower
The staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Meniscus Educational Institute and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
To access the learning assessment and evaluation form online, visit education.annenberg.net/jpl16-sessions.
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form) will be able to download a statement of credit.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 ACPE
- 1.00 ANCC
- 1.00 Attendance